Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’
Schöffski, P., Wozniak, A., Stacchiotti, S., Rutkowski, P., Blay, J.-Y., Lindner, L. H., Strauss, S. J., Anthoney, A., Duffaud, F., Richter, S., Grünwald, V., Leahy, M. G., Reichardt, P., Sufliarsky,Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx527
Date:
September, 2017
File:
PDF, 226 KB
english, 2017
File converter
More search results
More benefits 
